Work

Therapeutic Strategies Based on Hydroxybenzoic Acid Derivatives for Primary and Secondary Mitochondrial Disorders

Year: 2026
Type: dissertation
Abstract: Mitochondria are central organelles for cellular physiology, responsible for oxidative phosphorylation, ATP production, and the control of metabolic pathways such as fatty acid β-oxidation, the Krebs cycle, and parts of amino acid metabolism, among other functions. Any substantial alteration in their structure or function results in a wide range of diseases, from severe early-onset encephalopathies to common metabolic disorders such as type 2 diabetes or metabolic liver disease. In this context, coenzyme Q, CoQ, is a key component of the mitochondrial electron transport chain and an essential lipophilic antioxidant. Primary CoQ deficiencies are mitochondrial diseases caused by mutations in genes of this biosynthetic pathway. Clinically, they are highly heterogeneous, and may present with neurological phenotypes, nephropathies such as steroid-resistant nephrotic syndrome, myopathies, ataxia, epilepsy, retinopathies, or combinations of these features. Mutations in COQ2 and COQ5 are paradigmatic examples; COQ2 has been associated with severe infantile forms with renal and neurological involvement, as well as with a subtype of adult-onset multiple system atrophy, whereas COQ5, although much rarer, has been linked to patients with developmental delay, ataxia, encephalopathy, and retinitis pigmentosa. In all cases, the common outcome is a decrease in CoQ content and, consequently, impaired oxidative phosphorylation and increased oxidative stress. Traditionally, the main therapeutic option has been CoQ10 supplementation. However, although it is safe and increases plasma CoQ levels, its clinical efficacy is highly variable. Limited intestinal absorption, suboptimal delivery to some tissues and, in particular, to mitochondria, together with the heterogeneity of mutations and target organs, result in many patients showing only partial or modest responses. Given these limitations, alternative strategies have attracted increasing interest in recent years: on the one hand increasing the availability of the natural precursor 4- hydroxybenzoic acid, 4-HB, as a substrate enhancement therapy to boost residual enzyme activity, and on the other hand designing 4- HB analogues that act as bypass molecules for specific enzymatic steps, carrying in advance the modification that would normally be introduced by the defective enzyme. Beyond these monogenic forms, more modest alterations in CoQ homeostasis and mitochondrial function have also been implicated in highly prevalent metabolic diseases such as obesity and metabolic dysfunction-associated steatotic liver disease, MASLD. In patients with obesity, a negative correlation has been reported between CoQ content in white adipose tissue and body mass index. Likewise, in one of its main comorbidities, MASLD, there has been growing interest in recent years in the potential role of CoQ in disease pathophysiology and in its progression towards more severe inflammatory stages. In this framework, this thesis focuses on the evaluation of 4- HB and 4-HB analogues as alternative therapies in two complementary scenarios, on the one hand primary CoQ deficiencies due to mutations in the coq2 and coq5 genes, and on the other hand secondary mitochondrial dysfunction associated with obesity and MASLD. In the context of primary deficiencies, we developed and characterized two zebrafish models, coq2W212fs34* and coq5L229X, which recapitulate key features of the human disease, including developmental delay and motor abnormalities that lead to early lethality in both lines. Treatment with 4-HB does not improve CoQ content in the coq2W212fs34* model, supporting the notion that substrate enhancement therapy requires residual activity of the affected enzyme. In the coq5L229X model, we evaluated CoQ10 supplementation, several 4-HB analogues that could act as bypass therapies, together with other 4-HB analogues that have been proposed as promising in preclinical studies of primary CoQ deficiencies. In both the coq5L229X model and in human fibroblasts carrying the pathogenic COQ5 variants c.681+1G>A and c.352G>A, 4-HB analogues show no therapeutic effect, whereas CoQ10 supplementation increases CoQ10 content and provides a partial functional rescue.
Language: English
Open Access status: green
OpenAlex ID: W7171475128
Cites:
Cited by:
Related to: 10